<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Canavan, Neil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Punt, Cornelis J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Combination Biologic Therapy in Advanced Colorectal Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">The addition of a vascular endothelial growth factor antibody and an epidermal growth factor receptor inhibitor to chemotherapy had no benefit in advanced colorectal cancer. In fact, the combination had a significantly negative effect on progression-free survival. This article discusses the results of CAIRO2 [NCT00208546], a trial that was designed to investigate the effect of adding cetuximab to chemotherapy plus bevacizumab.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>